One thing income seekers don't want to see from the businesses they invest in is a major disruption to their incoming cash flows. Unfortunately for shareholders of (NYSE: ABBV), the drugmaker's top-selling product, Humira, lost patent-protected market exclusivity in the U.S. earlier this year.

U.S. Humira sales came in at $18.6 billion last year, or around 41% of total revenue. Its loss of exclusivity is creating a mighty big hole to fill, but there are some powerful new growth drivers in AbbVie's product portfolio.

The dividend payout has grown 285% since its inception in 2013. Let's measure AbbVie's strengths against the challenges it's facing to see if it's still a good dividend stock to buy.

Continue reading

Source Fool.com